POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITOR GDC-0980 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Jin, J. Y. [1 ]
Ware, J. [1 ]
Malhi, V. [1 ]
Upadhyay, S. [1 ]
Wu, J. [1 ]
Yan, Y. [1 ]
Lauchle, J. [1 ]
Holden, S. [1 ]
Derynck, M. [1 ]
Dresser, M. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [1] A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
    Wagner, A. J.
    Bendell, J. C.
    Dolly, S.
    Morgan, J. A.
    Ware, J. A.
    Fredrickson, J.
    Mazina, K. E.
    Lauchle, J. O.
    Burris, H. A.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW
    Wagner, A. J.
    Jayson, G. C.
    Gomez-Roca, C.
    Zee, Y. K.
    Morgan, J. A.
    Yan, Y.
    Ware, J.
    Mazina, K. E.
    Lauchle, J.
    Soria, J. C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 123 - 124
  • [3] Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
    Sutherlin, Daniel P.
    Belvin, Marcia
    Bao, Linda
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Friedman, Lori
    Heffron, Tim
    Patel, Sonal
    Olivero, Alan
    Lesnick, John
    Lewis, Cristina
    Marsters, James
    Nonomiya, Jim
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Tsui, Vickie
    Wallin, Jeff
    Wei, BinQing
    Weismann, Christian
    Zhu, Bing-Yan
    CANCER RESEARCH, 2011, 71
  • [4] Process development of PI3K inhibitor GDC-0980
    Humphries, Theresa
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [5] A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials
    Friedman, Lori S.
    Belvin, Marcia
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Guan, Jane
    Heffron, Tim
    Lesnick, John
    Lewis, Cris
    Nonomiya, Jim
    Olivero, Alan
    Patel, Sonal
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Dan
    Wallin, Jeff
    Zhu, Bingyan
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
    Makker, Vicky
    Recio, Fernando O.
    Ma, Ling
    Matutonis, Ursula
    Lauchle, Jennifer O'Hara
    Parmar, Hema
    Gilbert, Houston
    Wang, Yulei
    Koeppen, Hartmut
    Spoerke, Jill M.
    Lackner, Mark
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma
    Dolly, S.
    Wagner, A. J.
    Bendell, J. C.
    Yan, Y.
    Ware, J. A.
    Mazina, K. E.
    Holden, S. N.
    Derynck, M. K.
    De Bono, J. S.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE PAN-PHOSPHOINOSITIDE-3 KINASE (PI3K) INHIBITOR GDC-0941 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS
    Lin, J. Y.
    Budha, N.
    Ware, J.
    West, D.
    Iginla, S.
    Yan, Y.
    Holden, S.
    Derynck, M.
    Dresser, M.
    Dresser, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S81 - S81
  • [9] A FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE THE DUAL PI3K/MTOR INHIBITOR GDC-0980 ADMINISTERED QD IN PATIENTS WITH ADVANCED SOLID TUMORS OR NON-HODGKIN S LYMPHOMA (NHL)
    Bendell, J. C.
    Wagner, A. J.
    Dolly, S.
    Morgan, J. A.
    Papadatos-Pastos, D.
    Ware, J.
    Mazina, K. E.
    Lauchle, J.
    Burris, H.
    De Bono, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 162 - 163
  • [10] GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
    Wallin, Jeffrey J.
    Edgar, Kyle A.
    Guan, Jane
    Berry, Megan
    Prior, Wei Wei
    Lee, Leslie
    Lesnick, John D.
    Lewis, Cristina
    Nonomiya, Jim
    Pang, Jodie
    Salphati, Laurent
    Olivero, Alan G.
    Sutherlin, Daniel P.
    O'Brien, Carol
    Spoerke, Jill M.
    Patel, Sonal
    Lensun, Letitia
    Kassees, Robert
    Ross, Leanne
    Lackner, Mark R.
    Sampath, Deepak
    Belvin, Marcia
    Friedman, Lori S.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2426 - 2436
12345